STOCK TITAN

Aim Immunotech - AIM STOCK NEWS

Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.

AIM ImmunoTech Inc. (AIM) is a clinical-stage biopharmaceutical company pioneering RNA-based therapeutics for cancer, viral diseases, and immune disorders. This dedicated news hub provides investors and researchers with essential updates on clinical trials, regulatory developments, and strategic partnerships.

Access verified information about Ampligen clinical progress, Alferon N Injection research, and collaborative studies with global institutions. Our curated news collection covers FDA communications, trial phase results, intellectual property updates, and scientific conference presentations.

Key updates include oncology treatment advancements, antiviral therapy research, and partnership announcements with organizations like Japan's National Institute of Infectious Diseases. Bookmark this page for real-time access to AIM's latest developments in immuno-pharmaceutical innovation.

Rhea-AI Summary

AIM ImmunoTech Inc. has completed cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), a dsRNA product candidate for cancer, viral diseases, and immune disorders. CEO Thomas K. Equels emphasized the importance of this milestone for the company's development and commercial strategies, highlighting ongoing clinical trials for solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech Inc. announced positive results in testing Ampligen and Imfinzi in late-stage pancreatic cancer treatment. The combination was well-tolerated with no severe adverse events. The next safety cohort will start escalated dosing soon. Subjects will be monitored for response for up to 48 weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
-
Rhea-AI Summary
AIM ImmunoTech announces the release of the next CEO Corner segment featuring an overview of Metastatic Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial combining Ampligen® with Imfinzi® for the treatment of late-stage pancreatic cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
none
Rhea-AI Summary
AIM ImmunoTech announces the release of the next CEO Corner segment featuring an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need by Thomas Equels, the Chief Executive Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech appoints Dr. Charles Lapp as Consulting Medical Officer for ME/CFS and Long COVID Programs, aiming to develop Ampligen as a potential treatment. Dr. Lapp's expertise and dedication to FDA approval are highlighted, with CEO Equels praising his contribution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.29%
Tags
covid-19
-
Rhea-AI Summary
AIM ImmunoTech Inc. announces the publication of the CEO Corner segment discussing the potential synergistic effect of combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer, indicating promising results for the therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.93%
Tags
none
Rhea-AI Summary
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased anti-tumor immunity, indicating potential for broader application across various cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech Inc. reports financial results for 2023, highlighting positive data and milestones achieved in various clinical studies. The company aims to create stockholder value through operational, clinical, and regulatory initiatives. Key highlights include positive findings in treating pancreatic cancer and Post-COVID fatigue, as well as bolstering intellectual property. Financially, the company reported $13.1 million in cash and investments, with increased R&D and administrative expenses compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. will present at the MedInvest Biotech & Pharma Investor Conference on April 3rd, 2024. Thomas K. Equels, CEO, will discuss company updates and meet with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
conferences
Rhea-AI Summary
AIM ImmunoTech Inc. to discuss Q4/FY2023 results in a conference call on April 2, 2024, led by CEO Thomas K. Equels and Scientific Officer Christopher McAleer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Aim Immunotech

NYSE:AIM

AIM Rankings

AIM Stock Data

6.52M
67.24M
10.11%
12.54%
4.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
OCALA